EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real‐world evidence from the OPERA cohort

Gerald Pierone iD, Laurence Brunet iD, Jennifer S Fusco iD, Michael G Sension, Megan S Dunbar iD, Joshua Gruber, Douglas T Dieterich, Gregory P Fusco

HIV Medicine · 2025-11 · 26 (11) · 1707-1716

DOI: 10.1111/hiv.70105 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift HIV Medicine, online erschienen am 30.08.2025. Verfasst von Gerald Pierone und 7 weiteren Autor:innen. Beteiligte Einrichtung: Whole Family Health Center, Vero Beach, Florida, USA. Hauptthemen laut MEDLINE: HIV Infections, Heterocyclic Compounds, 3-Ring, Lamivudine, Emtricitabine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To compare the virologic effectiveness and discontinuation of the commonly prescribed fixed‐dose combination 3‐drug and 2‐drug regimens, bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) and dolutegravir/lamivudine (DTG/3TC), in virologically suppressed individuals in routine clinical care in the US.

Methods

From the OPERA cohort, ART‐experienced, virologically suppressed (viral load

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHeterocyclic Compounds, 3-RingLamivudineEmtricitabineTenofovirAnti-HIV AgentsAdenineHeterocyclic Compounds, 4 or More RingsHumansMalePyridonesFemalePiperazinesAdultOxazinesMiddle AgedViral LoadAlanineDrug CombinationsCohort StudiesTreatment OutcomeUnited StatesDrug SubstitutionAmidesDolutegravir

Stichwörter der Autor:innen

bictegravircohortdolutegravir/lamivudineregimen discontinuationvirologic failure

Substanzen

Heterocyclic Compounds, 3-RingPyridonesPiperazinesOxazinesLamivudineEmtricitabineTenofovirAnti-HIV AgentsAlanineAdenine

Autor:innen und Institutionen

  • Whole Family Health Center, Vero Beach, Florida, USA.
  • Epividian, Raleigh, North Carolina, USA.
  • CAN Community Health, Fort Lauderdale, Florida, USA.
  • Gilead Sciences, Inc., Foster City, California, USA.
  • Mount Sinai Health System, New York, New York, USA.

ORCID-Profile: Gerald Pierone, Laurence Brunet, Jennifer S Fusco, Megan S Dunbar

Förderung

  • Gilead Sciences

Zitieren

APA

Pierone, G., Brunet, L., Fusco, J. S., Sension, M. G., Dunbar, M. S., Gruber, J., Dieterich, D. T., & Fusco, G. P. (2025). Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real‐world evidence from the OPERA cohort. HIV Medicine, 26(11), 1707-1716. https://doi.org/10.1111/hiv.70105

Vancouver

Pierone G, Brunet L, Fusco JS, Sension MG, Dunbar MS, Gruber J, et al. Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real‐world evidence from the OPERA cohort. HIV Medicine. 2025;26(11):1707-1716. doi:10.1111/hiv.70105

BibTeX
@article{Pierone2025,
  author = {Pierone, Gerald and Brunet, Laurence and Fusco, Jennifer S and Sension, Michael G and Dunbar, Megan S and Gruber, Joshua and Dieterich, Douglas T and Fusco, Gregory P},
  title = {Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real‐world evidence from the OPERA cohort},
  journal = {HIV Medicine},
  year = {2025},
  volume = {26},
  number = {11},
  pages = {1707--1716},
  doi = {10.1111/hiv.70105}
}
Kostenlos starten →